A comparative trial of sequential bilateral and unilateral right sided priming repetitive transcranial magnetic stimulation on the severity of depressive symptoms in major depressive disorder.

Healthscope0 个研究点目标入组 176 人开始时间: 2010年11月17日最近更新: 2020年1月13日

试验速览

暂无简介。

•1.Have a Diagnostic and Statistical Manual -IV (DSM-IV) diagnosis of a major depressive episode.
•2. Have failed to respond to adequate antidepressant medical therapy. This will be defined by at least two courses of antidepressant medication (from two medication classes) at therapeutic doses for a minimum of six weeks. Adequate daily dose will be considered to be a minimum of: 150mg of Imipramine or equivalent for tricyclic antidepressants, 20mg of Fluoxetine or equivalent for serotonin re-uptake inhibitors, 600mg of Moclobemide, 600mg of Nefazadone, 150mg of Venlafaxine, 60mg of Phenelzine or equivalent for monoamine oxidase inhibitors
•3. Have a Hamilton Depression Rating Scale of > 16 (moderate – severe depression)
•4. Have had no increase or initiation of new antidepressant therapy in the 4 weeks prior to screening.

•Patients who:
•1. Have an unstable medical condition, neurological disorder or any history of a seizure disorder or are currently pregnant or lactating,
•2. In the opinion of the investigator, are a sufficient suicidal risk to require immediate electro-convulsive therapy,
•3. Have a current DSM IV diagnosis of substance abuse or dependence disorder, a diagnosis of a personality disorder or another axis 1 disorder.

发起方

Healthscope